The FDA has authorised Ziihera, an intravenous remedy for sure sufferers with unresectable or metastatic HER2-positive biliary tract most cancers.
The Meals and Drug Administration has authorised Ziihera (zanidatamab-hrii) for the remedy of adults with beforehand handled, unresectable or metastatic HER2-positive biliary tract most cancers (BTC).
Ziihera, the primary twin HER2-targeted bispecific antibody authorised for this affected person inhabitants in america, obtained accelerated approval primarily based on a 52% goal response charge (ORR) and a median length of response of 14.9 months within the section 2b HERIZON-BTC-01 medical trial, based on a information launch from producer Jazz Prescription drugs.
The accelerated approval of Ziihera at 50 milligrams per milliliter for injection for intravenous use could also be contingent upon verification in a confirmatory trial, with section 3 HERIZON-BTC-302 confirmatory trial at the moment ongoing, based on the information launch.
Glossary
Unresectable: tumors that can’t be surgically eliminated.
Intravenous: remedy given by way of the vein.
Metastatic: most cancers that has unfold from the place it began.
Goal response charge (ORR): sufferers who responded partially or fully to remedy.
Breakthrough remedy designation: a course of designed to expedite the event and evaluate of medication which might be supposed to deal with a critical situation and preliminary medical proof signifies that the drug might reveal substantial enchancment over out there remedy on a clinically important endpoint, based on the FDA’s web site.
Boxed Warning: referred to as a “black field” warning, is probably the most critical warning the FDA can problem for a drug.
“BTC is a devastating illness with a poor prognosis and five-year survival charges below 5% within the metastatic setting. Sufferers with unresectable or metastatic HER2-positive BTC have had a excessive unmet want with restricted remedy choices and few authorised therapies,” stated Dr. Rob Iannone, govt vice chairman, world head of analysis and improvement, and chief medical officer of Jazz Prescription drugs, within the information launch. “The approval of Ziihera, which beforehand obtained breakthrough remedy designation from the FDA for this indication, is a vital advance and presents the primary and solely twin HER2-targeted bispecific antibody and chemotherapy-free remedy for sufferers residing with BTC. We look ahead to advancing analysis of [Ziihera] in BTC and different HER2-expressing stable tumors, with the objective of bettering outcomes for extra individuals recognized with these difficult-to-treat HER2-positive cancers.”
Outcomes from HERIZON-BTC-01 had been beforehand reported on the American Society of Medical Oncology Annual Conferences in 2023 and 2024 and printed in The Lancet Oncology. In line with the information launch, the drug’s efficacy was evaluated amongst 62 sufferers with HER2-positive BTC.
The drug comes with a Boxed Warning for embryo-fetal toxicity, noting that publicity to the drug throughout being pregnant could cause embryo-fetal hurt. The security profile of Ziihera was demonstrated amongst 80 sufferers in HERIZON-BTC-01, with critical negative effects occurring in 53% of sufferers. The commonest negative effects occurring in at the very least 20% of sufferers had been diarrhea, infusion-related response, stomach ache and fatigue. Severe negative effects amongst greater than 2% of sufferers included biliary obstruction (15%), biliary tract an infection (8%), sepsis (8%), pneumonia (5%), diarrhea (3.8%), gastric obstruction (3.8%) and fatigue (2.5%). One affected person skilled a deadly aspect impact of hepatic (liver) failure, and affected person discontinuation on account of negative effects occurred in 2.5% of sufferers.
“As a medical investigator and medical oncologist targeted on advancing the care of sufferers with biliary tract and liver cancers, I’ve skilled firsthand the numerous unmet want for efficient therapies for sufferers with these ailments,” stated Dr. James Harding, affiliate attending, Gastrointestinal Oncology and Early Drug Growth Providers, at Memorial Sloan Kettering Most cancers Heart, within the information launch. “[Ziihera] has demonstrated antitumor exercise and is now a brand new choice for sufferers with HER2-positive biliary tract most cancers. I look ahead to continued and profitable drug improvement for sufferers with biliary tract most cancers.”
“Metastatic biliary tract most cancers, BTC, locations a major burden on sufferers, affecting their high quality of life and their emotional and psychological well-being, in addition to that of their households,” stated Stacie Lindsey, CEO and founding father of the Cholangiocarcinoma Basis within the information launch. “The approval of Ziihera presents a promising remedy choice. It offers sufferers and their family members the potential for extra time collectively and an improved high quality of life, which is invaluable for the whole BTC group.”
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
